Key insights from lung cancer research at ASCO 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

ASCO 2025: Importance of early testing in metastatic prostate cancer

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Disparities in mammogram screening amongst LGBTQ+ populations

New MOAs in prostate cancer treatment - what’s next?

Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Exploring colorectal cancer in Hispanic/Latino populations through multi-omics analysis of MYC gene and WNT signalling pathway alteration